Abivax Says Scorpion Capital Report Contains Inaccurate, Misleading Claims

PUBT · 12h ago
Abivax Says Scorpion Capital Report Contains Inaccurate, Misleading Claims
  • Abivax disputed Scorpion Capital's November 20, 2026, report, calling numerous statements inaccurate or misleading.
  • It reaffirmed confidence in Phase 3 ABTECT results supporting a US FDA new drug application filing by year-end.
  • Scorpion disclosed a short position and plans to cover a substantial portion upon publication, according to the response.
  • A detailed review is underway, with further updates expected.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611201632PRIMZONEFULLFEED1001304750) on November 20, 2026, and is solely responsible for the information contained therein.